We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Acadia (ACAD) Q4 Earnings & Revenues Fall Shy of Estimates
Read MoreHide Full Article
Acadia Pharmaceuticals Inc. (ACAD - Free Report) reported a fourth-quarter 2021 loss of 27 cents per share, wider than the Zacks Consensus Estimate of a loss of 24 cents. In the year-ago quarter, the company incurred a loss of 42 cents per share.
Total revenues, comprising net sales of Acadia's only marketed drug Nuplazid (pimavanserin), increased 8% year over year to $130.8 million for the fourth quarter, driven by Nuplazid volume growth. The top line, however, missed the Zacks Consensus Estimate of $135 million. Nuplazid sales fell below market expectation in the reported quarter.
Nuplazid is the first and the only FDA-approved treatment for hallucinations and delusions associated with Parkinson’s disease psychosis.
Shares of Acadia were down 7.7% in after-market trading on Monday, following the weaker-than-expected earnings announcement. The stock has plunged 46.1% in the past year compared with the industry’s 36.6% decline.
Image Source: Zacks Investment Research
Full-Year Results
For 2021, Acadia generated total revenues of $484.1 million compared with $441.8 million recorded in 2020.
For the year, the company reported a loss of $1.05 per share compared with a net loss of $1.79 per share in 2020.
Quarter in Detail
Research and development (R&D) expenses were $67.1 million for the quarter, up 8.1% from the year-ago quarter.
Selling, general and administrative (SG&A) expenses were $105.8 million, down 12.4% year over year.
As of Dec 31, 2021, Acadia had cash, cash equivalents and investments worth $520.7 million compared with $540.3 million as of Sep 30, 2021.
2022 Guidance
Acadia expects Nuplazid net sales of $510-$560 million for 2022. The Zacks Consensus Estimate for the metric is pegged at $557.9 million.
The company expects R&D expenses of $355-$375 million, while SG&A expenses are expected to be $360-$380 million in 2022.
Pipeline Updates
In February 2022, Acadia resubmitted the supplemental new drug application (“sNDA”) to the FDA for pimavanserin for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis.
The FDA had issued a complete response letter (“CRL”) to the sNDA for Nuplazid in April 2021.
Acadia has other promising pipeline candidates that are progressing well.
In December 2021, the company announced positive top-line data from the phase III Lavender study, which evaluated the safety and efficacy of its pipeline candidate, trofinetide, for the treatment of Rett syndrome. The study met its co-primary endpoints.
Acadia expects to file a new drug application (“NDA”) for trofinetide to treat Rett syndrome around mid-2022.
The company is evaluating ACP-044 for the treatment of postoperative pain following bunionectomy surgery in a phase II study. Top-line data from the study is anticipated later in the first quarter of 2022.
In January 2022, Acadia entered a collaboration agreement with Stoke Therapeutics, Inc. (STOK - Free Report) to discover, develop and commercialize novel RNA-based medicines for treating neurodevelopmental diseases of the central nervous system (“CNS”). The collaboration looks like a good strategic fit for Acadia to boost its pipeline of candidates being developed for treating various CNS disorders.
The partnership is looking to leverage Stoke’s RNA-based capabilities with Acadia’s expertise in neuroscience drug development for discovering multiple RNA-based treatments in severe and rare genetic neurodevelopmental diseases, including SYNGAP1 syndrome, Rett syndrome and an undisclosed neurodevelopmental target.
Acadia and Stoke will share all costs and profits equally for the SYNGAP1 program worldwide.
Acadia Pharmaceuticals Inc. Price, Consensus and EPS Surprise
Image: Bigstock
Acadia (ACAD) Q4 Earnings & Revenues Fall Shy of Estimates
Acadia Pharmaceuticals Inc. (ACAD - Free Report) reported a fourth-quarter 2021 loss of 27 cents per share, wider than the Zacks Consensus Estimate of a loss of 24 cents. In the year-ago quarter, the company incurred a loss of 42 cents per share.
Total revenues, comprising net sales of Acadia's only marketed drug Nuplazid (pimavanserin), increased 8% year over year to $130.8 million for the fourth quarter, driven by Nuplazid volume growth. The top line, however, missed the Zacks Consensus Estimate of $135 million. Nuplazid sales fell below market expectation in the reported quarter.
Nuplazid is the first and the only FDA-approved treatment for hallucinations and delusions associated with Parkinson’s disease psychosis.
Shares of Acadia were down 7.7% in after-market trading on Monday, following the weaker-than-expected earnings announcement. The stock has plunged 46.1% in the past year compared with the industry’s 36.6% decline.
Image Source: Zacks Investment Research
Full-Year Results
For 2021, Acadia generated total revenues of $484.1 million compared with $441.8 million recorded in 2020.
For the year, the company reported a loss of $1.05 per share compared with a net loss of $1.79 per share in 2020.
Quarter in Detail
Research and development (R&D) expenses were $67.1 million for the quarter, up 8.1% from the year-ago quarter.
Selling, general and administrative (SG&A) expenses were $105.8 million, down 12.4% year over year.
As of Dec 31, 2021, Acadia had cash, cash equivalents and investments worth $520.7 million compared with $540.3 million as of Sep 30, 2021.
2022 Guidance
Acadia expects Nuplazid net sales of $510-$560 million for 2022. The Zacks Consensus Estimate for the metric is pegged at $557.9 million.
The company expects R&D expenses of $355-$375 million, while SG&A expenses are expected to be $360-$380 million in 2022.
Pipeline Updates
In February 2022, Acadia resubmitted the supplemental new drug application (“sNDA”) to the FDA for pimavanserin for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis.
The FDA had issued a complete response letter (“CRL”) to the sNDA for Nuplazid in April 2021.
Acadia has other promising pipeline candidates that are progressing well.
In December 2021, the company announced positive top-line data from the phase III Lavender study, which evaluated the safety and efficacy of its pipeline candidate, trofinetide, for the treatment of Rett syndrome. The study met its co-primary endpoints.
Acadia expects to file a new drug application (“NDA”) for trofinetide to treat Rett syndrome around mid-2022.
The company is evaluating ACP-044 for the treatment of postoperative pain following bunionectomy surgery in a phase II study. Top-line data from the study is anticipated later in the first quarter of 2022.
In January 2022, Acadia entered a collaboration agreement with Stoke Therapeutics, Inc. (STOK - Free Report) to discover, develop and commercialize novel RNA-based medicines for treating neurodevelopmental diseases of the central nervous system (“CNS”). The collaboration looks like a good strategic fit for Acadia to boost its pipeline of candidates being developed for treating various CNS disorders.
The partnership is looking to leverage Stoke’s RNA-based capabilities with Acadia’s expertise in neuroscience drug development for discovering multiple RNA-based treatments in severe and rare genetic neurodevelopmental diseases, including SYNGAP1 syndrome, Rett syndrome and an undisclosed neurodevelopmental target.
Acadia and Stoke will share all costs and profits equally for the SYNGAP1 program worldwide.
Acadia Pharmaceuticals Inc. Price, Consensus and EPS Surprise
Acadia Pharmaceuticals Inc. price-consensus-eps-surprise-chart | Acadia Pharmaceuticals Inc. Quote
Zacks Rank & Stocks to Consider
Acadia currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the biotech sector are Dynavax Technologies Corporation (DVAX - Free Report) and Kaleido Biosciences, Inc. , both carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Dynavax’s earnings estimates have been revised 10.3% upward for 2022 over the past 60 days. The stock has rallied 42.1% in the past year.
Earnings of Dynavax have surpassed estimates in each of the trailing four quarters.
Kaleido Biosciences’ loss per share estimates have narrowed 11.3% for 2022 over the past 60 days.
Earnings of Kaleido Biosciences have surpassed estimates in three of the trailing four quarters and missed the same once.